MONTREAL, Oct. 06, 2017 -- I-MED Pharma, Inc., a Canadian company specialized in dry eye diagnosis and management, announced today the appointment of AMWO Farma IVS as its exclusive distributor for the I-PEN® Tear Osmolarity System as well as the I-DROP® and I-LID ‘N LASH® dry eye products in Denmark, Sweden and Norway.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a0c0fde2-b539-4851-adf7-8ed42648e5fb
Daniel Hofmann, President of I-MED commented, “We are pleased to have the opportunity to introduce our innovative products to Scandinavian eye care professionals and to give them new options for rapid, reliable diagnosis and effective, long lasting symptom relief for their dry patients.”
AMWO Farma CEO Claus Oldenburg said, “We are excited about our new relationship with I-MED Pharma and we look forward to introducing the I-PEN®, as well the Ocular Surface Disorder (OSD) line of products to ophthalmologists, optometrists and their patients. I-MED Pharma’s unique products offer a major leap forward in our efforts to improve the vision and quality of life of people with dry eye problems.”
I-MED Pharma is a privately held Canadian company, headquartered in Montreal, Quebec, servicing Canadian ophthalmologists, optometrists and the global eye care community. Established over twenty-five years ago, I-MED Pharma Inc. creates and distributes innovative medical, surgical and veterinary eye care products. It continually researches, develops and sources the most effective and advanced solutions to eye disorders like cataracts, corneal degenerations, dry eye, glaucoma and Meibomian gland disease.
I-MED Pharma is proud to have been at the forefront of treating Dry Eye Syndrome as a serious disease and investing heavily into education and developing effective dry eye products. Most recently, I-MED Pharma launched the world’s first hand-held in-vivo tear osmolarity test, the I-PEN® osmolarity device. I-MED Pharma’s ocular surface disease product range includes diagnostic tools, ocular hygiene, nutrition, dry eye drops and ocular occlusion devices.
For more information please email [email protected] or visit www.imedpharma.com.


Chinese Brands Are Taking Over Brazil — And It's Just Getting Started
Bill Ackman Eyes New Fund to Bet Against Market Complacency
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 



